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Abstract
Peanut allergies are a serious issue that must be monitored and treated effectively to
avoid severe adverse effects and death. In the last decade, their incidence has increased
significantly, due to indeterminate factors. Because people typically do not outgrow
peanut allergies and the effects of exposure can be life-threatening, it is important that a
cure or management method is developed and refined. Recent research regarding
treatment for peanut allergies has focused on the use of immunotherapy, a process aimed
at desensitizing children's immune systems so that they do not reject foods that contain
peanuts. Some studies utilizing immunotherapy have provided positive findings, while
others show less promising results. Working within the limitations imposed by safety
concerns, researchers are seeking to find a reliable treatment that can be utilized in more
cases, whether it is through oral, sublingual, or subcutaneous immunotherapy. Since
those with peanut allergies are gradually composing a larger percentage of the
population, this area of research is relevant and could prove beneficial in improving and
saving the lives of many individuals.
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Use of Immunotherapy in the Treatment of Nut Allergies in the Pediatric Population
Food allergies are a growing problem, especially in the United States. One study
by the Centers for Disease Control and Prevention (CDC) showed that food allergies
among children increased by about 50% between the years 1997 and 2011 (FARE, n.d.).
In the last decade, the number of children living with peanut allergies has also increased
dramatically, tripling between 1997 and 2008 (FARE, n.d.). In fact, peanuts currently
comprise approximately 0.6-1/3% of all allergens causing reactions in the United States.
According to Yu, Weldon, Neale-May, and Nadeau (2012), “Peanut allergy, which
affects an estimated 0.6% of U.S. adults and more than 1% of children, is the leading
cause of food related fatal anaphylaxis in the United States” (p. 1). This once-rare issue
has now become the most common cause of fatal allergic reactions to food, making it an
area greatly in need of an effective and reliable cure, rather than just an emergency
treatment (Anagnostou & Clark, 2015).
Many have tried to determine an explanation for this significant increase in peanut
allergies in children, but as of yet no one factor has been proven to be the cause. One
theory under speculation is the delayed introduction of young children to peanuts. For
several years, many medical experts advised that all parents wait until their children
reached recommended ages before they were given peanuts and other potentially
allergenic foods. With these recommendations came increased awareness of specific food
allergies and the dangers they can cause. While pediatricians still recommend using
caution with early exposure, many believe that avoidance may cause more harm than
good and that delaying exposure actually increases the chances the child will display
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hypersensitivity (UCLA Health, 2010). A second theory is the impact of our current
society’s focus on living ‘clean’ and trying to stay as healthy as possible. It is thought
that perhaps when people prevent their bodies from exposure to bacteria, illnesses, and
other things they consider to be harmful, it actually causes their immune systems to be
more sensitive to minor invaders such as pollen and peanut proteins. Another proposal is
that the way peanuts are cooked today makes them more allergenic. The peanut-roasting
process manufacturers use supposedly modifies the sugar in peanuts, thereby increasing
the ability of the peanuts to attack the immune system (Hendrick, 2010). At one point, it
was thought that children’s allergies to peanuts may be caused by their mothers’
ingestion of peanuts during pregnancy. However, this was soon disproved by a study
wherein expectant mothers avoided peanuts. It was found that “[a]voidance of peanut
consumption during pregnancy and lactation failed to reduce the prevalence of peanut
allergy. Early introduction of peanut may actually promote tolerance and reduce the risk
of peanut allergy” (Anagnostou & Clark, 2015, p. 71).
Despite the lack of a confirmed cause or causes, it has been found that peanut
allergies are definitely on the rise. This significant rise necessitates a safe and reliable
treatment which can effectively prevent allergic reactions to peanuts. Immunotherapy is
currently on the front lines of a growing field striving toward the elimination of peanut
hypersensitivities. The goal of immunotherapy researchers is that the affected population
will someday be able to live day-to-day without constant fear of accidentally ingesting
this seemingly harmless ingredient that turns bodies against themselves.
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Pathophysiology of Allergic Response
The body’s immune system works constantly to protect a person from foreign
material it may encounter in its environment. Sometimes, however, its defensive
mechanisms bring about a negative result and the immunity which is meant for good may
actually place the body in more danger. This is the case with hypersensitivities such as
peanut allergies. The immune processes of the body are carried out by the lymphatic
system. One of the central lymphoid organs is the bone marrow, which produces
lymphocytes. After lymphocytes have been formed, they differentiate into either B or T
lymphocytes. Of these two types, B lymphocytes are key players in allergic responses
(Lewis, 2011).
When a hypersensitive person ingests peanuts, the peanut proteins are viewed by
the body as an antigen and it quickly reacts to try to rid the body of it. The first time this
person consumes peanuts, the proteins enter the bloodstream, where they are detected by
B lymphocytes. This encounter activates a transformation of the B lymphocytes into
plasma cells, which have the ability to produce antibodies against the peanut antigen. The
specific type of antibodies – also called immunoglobulins – created are called
immunoglobulin E (IgE) antibodies. These newly-formed IgE antibodies attach
themselves to another type of cell, either mast cells or basophils, where they wait for the
allergen to enter the body again. Thus, this initial encounter with the allergen produces no
systemic effects. However, when the person ingests peanuts for the second time, the
antibodies attached to the mast cells bind to the peanut proteins, thereby initiating an
allergic response. Granules inside the mast cells break down and quickly release many
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powerful chemical mediators, including histamine and serotonin, which exert their effects
on various body systems (Lewis, 2011).
Chemical Mediators and Their Actions
One type of chemical mediator released by the mast cells are called
anaphylatoxins. The three complement proteins specific to allergic reactions are C3a,
C4a, and C5a. These three complement fragments are known as anaphylatoxins because
they combine their effects to produce anaphylaxis or anaphylactic shock. They cause the
smooth muscles in the body to contract and make the blood vessels more permeable. C5a,
which is the most influential of the three proteins, and C3a also stimulate the release of
histamine, another chemical mediator, by activating submucosal mast cells (Janeway,
Travers, Walport, & Shlomchik, 2001).
Histamine, one of the main players in the anaphylactic response, is a very potent
vasodilator of the small blood vessels. It also causes endothelial cell contraction, which
provides openings for easier passage of proteins, cells, and fluids. This increased
capillary permeability may cause edema to occur due to the loss of fluid into interstitial
spaces. In turn, the loss of intravascular fluid along with vessel dilation causes a drop in
blood pressure. Histamine also causes constriction of the bronchi. All of the above effects
occur when histamine stimulates H1 receptors (Lehne, 2010) (Moriber, 2013).
Leukotrienes, prostaglandins, kinins, and serotonin are all chemical mediators that
also work to constrict smooth muscle, constrict bronchi, vasodilate, and increase
permeability of vessels. Leukotrienes constrict the bronchi and enhance the effects of
histamine to constrict smooth muscle. The bronchoconstriction effects of leukotrienes are
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actually slower, longer-lasting, and more potent than those of histamine. Together,
leukotrienes and histamine help activate and sustain the allergic response.
(Hammarström, 1983) (Grossman, 2013).
Platelet-activating factor is another important mediator of the allergic response.
This chemical is produced from the lipids stored in cell membranes; its main action is to
put the aggregation of platelets into effect. It also draws in and activates eosinophils and
neutrophils. Platelet-activating factor causes bronchospasm as well as wheals and flaring
(Grossman, 2013).
Clinical Symptoms of Allergic Reaction
All of the above effects caused by the many chemical mediators released into
various parts of the body combine to inflict a deadly outcome for hypersensitive
individuals if antagonistic action is not taken quickly. As the bronchi constrict, it
becomes more and more difficult to breathe. Affected children may speak in a hoarse
voice due to their constricted airways or cough in an attempt to expel more air. Wheezing
and stridor may be heard upon breathing as the bronchi narrow and gas exchange
becomes more difficult. Tachypnea may also occur, eventually progressing to respiratory
arrest.
The cardiovascular effects can also be severe and life-threatening. As mentioned
above, the vessels dilate and vascular permeability increases, causing a low vascular
volume. This leads to a decrease in blood pressure and increase in heart rate, which may
in turn cause vascular collapse, dysrhythmia and cardiac arrest to develop (Lewis, 2011).
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The neurological system is also affected by the chemical mediators. When
vasodilation occurs in the head, the child may experience a headache due to the increased
pressure on the brain. The decreased oxygen supply to the brain due to impaired gas
exchange, as well as lower circulating blood volume, can cause a child to feel dizzy and
possibly lose consciousness. A decrease in oxygen supply to nerves can also cause
paresthesia. The individual may also experience a sense of impending doom (Lewis,
2011).
The allergic person can also develop unpleasant integumentary symptoms.
Urticaria, or hives, occur as a result of the vasodilatory and fluid shift effects of
histamine. Fluid that escapes from the increasingly-permeable vessels forms collections
of fluid under the skin known as wheals anywhere on the body. Blood vessels underneath
the wheals may dilate as a result of sympathetic nervous system stimulation, producing
flaring of the wheals. Pruritis, or itchy skin, and erythema, a general or localized
reddening of the skin, are two other symptoms that are also caused by the release of
histamine. Angioedema may also occur. This involves the build-up of fluid, much like
with urticaria, but the fluid collects under deeper layers of the skin. Unlike with urticaria,
angioedema occurs in areas such as the eyelids, genitalia, and gastrointestinal tract. Pain
or burning are sometimes felt when the swelling affects sensitive areas such as the
gastrointestinal (GI) tract. This swelling is especially serious when it reaches the larynx
and other airway structures, so it is important that the individual’s airway be protected. It
may take as long as 24 hours for the swelling to subside (Lewis, 2011).
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The allergic response also causes GI effects. As mentioned above, angioedema
can lead to acute pain in the abdominal region. Cramping, nausea, vomiting, and diarrhea
may all also occur. These symptoms are further evidence that the body is making a
deliberate effort to get rid of the antigens it considers to be harmful (Lewis, 2011).
Traditional Treatment of Peanut Allergies
As Blumchen et al. (2010) points out, peanut allergies are a unique and persistent
allergen:
Some food allergies in early childhood, like cow’s milk and hen’s egg allergy,
usually resolve over time. In contrast, peanut allergy tends to persist over a
lifetime, and only about 20% of young children outgrow their disease. It has been
reported that the severity of future allergic reactions to peanuts cannot be
predicted from former allergic reactions in the patient’s history. Thus, most
patients with peanut allergy face the fear of anaphylaxis throughout their life. This
constant uncertainty has a major psychological burden on the quality of life of the
children and their families. (p. 83)
The standard treatment for peanut allergies has remained the same for years. Affected
individuals avoid ingesting the allergen whenever possible, even if it means avoiding
restaurants and food from manufacturers that process peanuts. Parents may meticulously
read nutrition labels of any food they give their child and do anything else they have to in
order to prevent their child from being exposed. In addition, many children with peanut
allergies also are allergic to one or more tree nuts, adding to the need to be very careful
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about what the child ingests (The Peanut Institute, n.d.). As Blumchen et al. (2010) noted
above, this places extreme stress on children and all those involved in their care.
However, despite precautionary measures, these children still sometimes ingest
peanuts – whether it be through accidental or intentional means. The standard and most
effective treatment is Epinephrine. Epinephrine is the prototype of a drug class called
sympathomimetics. Specifically, it acts on all four adrenergic receptors – alpha1, alpha2,
beta1, and beta2 – to activate each of their effects. These effects include vasoconstriction,
increased contractility and heart rate, and bronchodilation. Epinephrine causes rapid
activation of the adrenergic receptors and thus, relieves the life-threatening vasodilation
and bronchoconstriction brought on by the anaphylaxis. Blood pressure quickly
normalizes, heart rate increases, and dyspnea is relieved – all within seconds or minutes
(Lehne, 2010).
An epinephrine 1:1000 preparation is available inside what is called an EpiPen.
An adult EpiPen dose is 0.3 mg of epinephrine, while the EpiPen Jr. injects 0.15 mg with
each dose. In some cases, one dose is not sufficient to relieve the individual’s symptoms.
When this occurs, another dose may be given. The EpiPen is easy to use and can be selfadministered; it is loaded with an intramuscular needle which self-ejects when pressure is
applied. After the cap is removed, the pen must be firmly pressed into the vastus lateralis
muscle, which is located on the lateral aspect of the thigh. After the dose is administered,
the injection site should be massaged for a few seconds to promote optimal absorption. A
small marker in the window of the pen indicates successful injection. Even if symptoms
improve, it is recommended that the individual seek medical care because epinephrine
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has a very short half-life and the anaphylactic symptoms may return. Care providers can
administer prednisone if needed and observe for continued symptoms. It is important that
individuals with known peanut allergies always have access to an EpiPen, because
exposure may be encountered even in an unexpected setting. Since EpiPens typically
expire after one to two years, it is important to check often to make sure the medication is
still current. Most EpiPens have small windows that allow the owner to check for agerelated discoloration, which is a good indication that the epinephrine has lost its original
potency (EpiPen, n.d.) (Lehne, 2010).
Background and History of Immunotherapy Treatment
The idea of immunotherapy has been around for centuries. It is said that King
Mithridates VI, who lived 132–63 B.C., attempted to make himself immune to snake
venom by exposing himself to increasing doses of the poison. Since this recorded event,
there have been numerous other occurrences of a harmful reaction being treated with
increasing amounts of the reaction-causing substance. Allergen-specific immunotherapy
was first studied clinically in humans by scientists Leonard Noon and John Freeman in
1911. They injected extracts of pollen into patients with hay fever and observed the
results. Their research paved the way for the use of immunotherapy in many other studies
and cases (Ring & Gutermuth, 2011).
Allergy injections are a common form of immunotherapy used today. Used
mainly in patients with seasonal allergies, this therapy involves the routine injection of
tiny amounts of allergens with the goal of triggering activation of the immune system
without creating a full-scale allergic response. The results of this treatment range from
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slow improvement of symptoms to complete desensitization to the injected allergens.
Desired results may take years to achieve, however, and even then in some cases, the
shots may still have to be administered in order for desensitization to continue (Mayo
Clinic Staff, 2015). Today, the use of immunotherapy in treating peanut allergies is a
major area of research yielding promising, yet controversial results and opinions (Ring &
Gutermuth, 2011).
Study Participants
Before each individual study begins, the group of researchers will determine
inclusion and exclusion criteria for potential participants in their research. Usually a
general age population – adults or children – is agreed upon, then the recruiting begins
from there. Volunteers go through a screening process to see if they meet the proper
criteria for the study. A detailed medical history is typically taken, for safety and also so
that comorbidities such as asthma and other allergic disorders can be taken into account
when the research results are analyzed. Often, if a person has a history of severe
anaphylactic reactions or if they have another serious chronic illness, they will be
excluded from the study for safety reasons. Tests to confirm their hypersensitivity to
peanuts, such as a skin-prick test, are typically performed to ensure the allergy actually
exists. Some studies will utilize a group of healthy individuals to receive the treatment
alongside the allergic individuals. After the final selections for the study group have been
made, the immunotherapy process begins.
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Overview of Immunotherapy Process
Conducting studies utilizing immunotherapy treatment necessitates careful
planning and organizing, collaboration and recruiting, troubleshooting and preparedness.
This list is just a sampling of the many thought processes and methods that must be
present to conduct a well-established, reliable research study. The choices the researchers
make can affect the results of the study as well as the outcome of the patients.
While details such as the specific routes, dosages, timeframes, and populations
may vary according to the study being carried out, the general concept is the same. The
steps of the immunotherapy typically occur in the following order, although individual
studies may rearrange or omit steps depending on their research process: initial escalation
phase, build-up phase, maintenance phase, avoidance phase, and challenge phase.
Initial Escalation Phase
The first phase of immunotherapy usually takes place over one day in a controlled
clinical setting where all the participants may be observed throughout the process and
treated in the event of an emergency. A very tiny dosage of peanut protein is
administered, typically around one milligram (mg). In addition, a percentage of the
participants may receive a placebo substance instead. This initial dose is actually only
0.005-0.006% of the average amount of protein in a single peanut, 180-200 mg. After this
initial dose, the amount is doubled every 30 minutes until either a maximum dosage is
reached (around 50 mg) or the participant exhibits symptoms of an allergic response.
During this phase especially, it is important for the conductors of the study to have
epinephrine and other emergency equipment readily available in case there are any
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serious reactions. Some participants experience such severe symptoms from the
introduction of peanut proteins during the escalation phase that they cannot safely
continue with the study (Moffat, 2014).
Build-up Phase
On the day following the escalation period, the build-up phase begins. Each
participant is given the highest amount they were able to tolerate the day before and their
response is observed. The participant is then instructed to continue this daily dosage at
home, usually with other food. At frequent intervals, typically every week or sometimes
every other week, the participant returns to the clinical setting for escalation of the
dosage. This phase may continue for months to a year, depending on how long it takes for
the participant to reach set dosages. At first, the escalation is usually by 50-100%, then
once the individual reaches a determined dose, the build-up rate is decreased. Often
during this phase and occasionally during other phases, the participants or the parents of
the participants are required to keep a diary recording observations of important details
such as reactions, illnesses, missed dosages, and any other data that may be relevant
(Varshney et al, 2011).
Maintenance Phase
The build-up phase continues until the maintenance dose is reached. In one study,
this amount was set at 4000 mg, but it is typically anywhere from 1800-4000 mg. At this
point, the participant will ingest this amount every day for an extended period of time,
ranging from a month to several years. During this phase, around 50% usually experience
adverse effects to the peanut proteins (Varshney et al, 2011) (Moffat, 2014).
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Challenge Phase
During the maintenance phase, a challenge test is delivered to determine whether
the participant truly has become tolerant to the peanut allergens. The challenge test
involves the delivery of increased amounts of peanut proteins over short increments of
time. Over this timeframe, the total accumulated dosage adds up to the highest amount
the participant has ever had, often around 5000 mg (Varshney et al, 2011).
Avoidance Phase
An avoidance phase is sometimes incorporated into immunotherapy. During this
phase, the participant discontinues all daily doses of peanut protein. After about two to
three months of avoiding the allergen completely, the participant receives another oral
challenge to reassess their sensitization. Typically over half of the study participants are
able to tolerate this delayed dosage, but research has shown that the longer the avoidance
phase lasts, the more likely the participant is to experience a reaction when he consumes
peanuts again (Moffat, 2014).
Types of Immunotherapy & Correlating Studies
There are several different types of peanut immunotherapy that have been studied.
Some have been more successful than others in terms of participant safety and positive
outcomes. The different routes that have been attempted include subcutaneous, oral,
sublingual, and epicutaneous. Along with exclusive peanut immunotherapy, a few other
treatments or methods have been combined to explore the effectiveness of different
methods. These methods include the use of a peanut vaccine and adjuvants such as antiIgE (Anagnostou & Clark, 2014).
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Subcutaneous Immunotherapy
The subcutaneous route of peanut immunotherapy was first attempted on a small
scale in a study that took place in 1992. Unfortunately, this study resulted in a high rate
of systemic reactions; 13.3% of the participants. Also, as a result of a pharmaceutical
error, one participant who had been receiving placebo dosages was accidentally given a
maintenance dose of peanut protein and ended up with fatal anaphylaxis. Besides these
cases, three of the participants of this study showed a significant reduction in allergic
symptoms. A second study utilizing subcutaneous therapy was conducted on 12 adult
patients. Some of the participants experienced an increased in their threshold for peanuts,
but just as in the earlier study, a high rate of systemic reactions was present. For this
reason, despite potential benefits, subcutaneous immunotherapy has been determined to
be an unsafe method at present for the experimental treatment of peanut allergies
(Anagnostou & Clark, 2014).
Oral Immunotherapy
Oral immunotherapy (OIT), unlike subcutaneous immunotherapy, has been shown
to be a safer method of conducting trials for those with peanut allergies. The rate of
systemic reactions, compared to that of subcutaneous therapy, is much lower. In addition,
more beneficial and promising results have been found. A study of children in the United
Kingdom resulted in 86% of the participants developing tolerance to the small amount
that might be ingested accidentally. The reactions in this study were mild and did not
require the use of epinephrine. In the United States, a similar study was performed with a
similar outcome. Although epinephrine was required on six occasions, the end result was
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that 93% of the children could tolerate 3.9 grams of peanut protein (equal to about 19-20
peanuts). Subsequent studies have shown a tolerance rate of 84%. Based on these and
other studies, oral immunotherapy appears to be a safe and effective method of
conducting research. The majority of recent studies have utilized oral methods with
substantial success (Anagnostou & Clark, 2014).
The first double blind, placebo-controlled study of oral peanut immunotherapy
was published in 2011. The study consisted of 28 peanut-hypersensitive children, aged
one to 16 years. Nineteen of the children received peanut flour in whatever food they
chose, while the other nine were given a similar placebo administration. The starting
dosage of the administrations was 0.1 mg. Early in the trial, three of the participants
dropped out because they experienced side effects. The other 16 children, however, were
able to complete the entire year of treatment and tolerate the final oral food challenge
(OFC) of 5000 mg of peanut protein (Varshney, 2011).
Another double blind, placebo-controlled study was conducted by Blumchen et al.
to evaluate the effectiveness of oral immunotherapy in 23 children ages 3-14 years old.
The participants followed a rush protocol in the first week, then build-up and
maintenance phases were implemented. Due to various factors, such as reactions, that
prevented further experimentation and personal adherence to the required regimen, only
14 of the original 23 participants ended up able tolerate the final maintenance dose of
500mg or more of whole peanut. During the rush period, one participant dropped out of
the study due to anxiety concerning the initial reaction that had occurred during the
beginning OFC confirming peanut allergies. The other 22 participants received an
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average of 14 servings of peanuts during the rush protocol week. The goal was for the
patients to be able to tolerate 500mg of peanut protein after undergoing the therapy.
However, only five children met this goal at the end of the rush protocol (Blumchen et
al., 2010).
A notable difference in IgE levels in the two groups was found, with an average
of 212 kUA/L in the less tolerant group and 9.1 kUA/L in the group able to tolerate
500mg. While the less tolerant received a tolerable daily maintenance dose, the others
underwent a long term buildup protocol. In all, 14 participants reached the 500mg daily
goal. The eight who did not reach the goal discontinued therapy for various reasons: four
experienced allergic reactions preventing them from continuing, one experienced
subjective allergic symptoms, and the other three dropped out for non-allergic reasons.
Thus, a protective dose was reached by 61% of the original group. After two subsequent
weeks of peanut avoidance, the children still showed an increased tolerance as compared
to their baseline before the study. Eight children were even able to tolerate a dose higher
than their maintenance amount. The study concluded that oral immunotherapy as a long
term buildup protocol seems to be safe and effective. Conversely, rush protocol was
noted to be minimally effective unless the participant had low levels of IgE. In addition,
the rush protocol was associated with a higher number of adverse reactions (Blumchen et
al., 2010).
Syed et al. conducted a study in 2014 to explore in more detail how oral
immunotherapy works on a cellular level, since the exact mechanisms by which
immunotherapy induces desensitization are not known. Specifically, this group examined
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changes that occurred in T cells, basophils, and antibodies. Two groups were selected to
be observed and compared. One group was undergoing oral immunotherapy, while the
other group was following traditional abstinence from peanut proteins. The study found
no significance differences in the amount of basophils and antibodies in each group.
However, an improvement in T cell function in the oral immunotherapy participants was
noted, as evidenced specifically by the hypomethylation of a protein in Treg cells called
forkhead box protein 3 (FOXP3). This was the first state to prove that in addition to being
increased as a result of tolerance, aiTreg cells are also “functionally suppressive” (p.
508). Interestingly, “aiTreg cells, despite being in relatively small numbers compared
with other immune cell subsets, have been shown be associated with natural loss of food
allergy (Syed et al., 2014).
Sublingual Immunotherapy
Sublingual immunotherapy (SLIT) is another route that appears to be somewhat
effective and yet still seems to be safe for routine studying. In 2011, a study was done on
19 hypersensitive participants using the sublingual route to deliver peanut proteins. This
study resulted in the control group being able to consume 1710 mg of peanut protein,
while the placebo group could only safely consume 86 mg. Another study resulted in
85% clinical desensitization to an average of 496 mg of peanut protein. Excluding
oropharyngeal symptoms, 94.7% of the participants were symptom-free, demonstrating a
high safety profile. When compared with oral immunotherapy, however, sublingual
immunotherapy requires the use of lower allergen doses and thus has not been shown to
be as effective as oral immunotherapy. In addition, less research involving sublingual
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immunotherapy has been performed, so more trials need to be conducted in order to
determine its potential (Anagnostou & Clark, 2014).
In 2012, another study using sublingual immunotherapy was conducted using
double-blind, randomized methods with a placebo control group. For the cohort group,
only volunteers aged 18-40 years were allowed to participate. Twenty weeks after the
start of the cohort group, younger individuals, aged 12 to 18 were permitted to join the
study. Each participant underwent several verification processes to confirm their allergy,
including a physician’s diagnosis, significant reaction to skin prick titration test or
detectable IgE proteins specific to peanuts, and a positive baseline double-blind, placebocontrolled food challenge (DBPCFC). Subjects were excluded if they had a history of
severe anaphylaxis, intubation, or another serious medical condition. Half of the 40
participants were randomly chosen to receive a sublingual form of peanuts, while the
other half received a placebo. The peanut preparation was made by extracting from the
allergenic portion of unroasted peanuts and combining it with “0.5% sodium chloride and
0.54% sodium bicarbonate at a pH of 6.8 to 8.4 as aqueous extracts in 50% glycerin”
(Fleischer et al., 2012, p. 127). The placebo was a simple mixture of phenol with caramel
coloring and glycerinated saline (Fleischer et al., 2012).
The escalation phase began with administration of a dose containing only
0.000165 micrograms (µg) of peanut protein. Every two weeks, three equal dosages were
given at least 30 minutes apart and then the participant was instructed to maintain the
same dose at home until the next escalation. If a participant failed the 3-dose
administration three times (two weeks apart), then a 1- or 2-dose administration was

IMMUNOTHERAPY FOR CHILD PEANUT ALLERGIES

22

allowed. Escalation continued until a dose of 660 µg was reached. At this point, single
doses were given, then two weeks of maintenance therapy was provided (Fleischer et al.,
2012).
During the maintenance phase, a daily dose of peanut protein ranging from 6501386 µg or a 420 mL dose of placebo was given until the 44th week. At this point, an
unblinding DBPCFC of 5g transpired. After the participants had undergone unblinding
and approximately one year of maintenance, they received a 10g OFC. Responders were
determined based on alterations in the level of IgE and IgG4, responses to another skin
prick test, and activation of basophils. In the group receiving peanut SLIT, 14 out of 20
were considered responders, compared with 3 out of 20 in the control group. The average
successfully-consumed dose (SCD) was 371mg at Week 44, an increased from 21mg at
baseline. On the other hand, the placebo subjects had a baseline average of 71mg and a
SCD of just 146 at 44 weeks. After 44 weeks, however, there was no significant
difference between the average SCDs of the two groups (Fleischer et al., 2012).
Also at 44 weeks, 17 members of the control group crossed over to receive a
peanut OFC. Eighty-eight percent were able to withstand the maximum dose of 3696mg.
Fifteen subjects underwent another OFC at 68 weeks. Three subjects were able to
consume 5g of peanut powder and two subjects could consume 10 g. The median SCD
increased from week 44 to 996 mg. The researchers concluded that a majority of
participants who undergo peanut SLIT safely experience a level of desensitization.
However, more studies are needed to determine whether peanut SLIT can be used
therapeutically (Fleischer et al., 2012).
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Epicutaneous Immunotherapy
Epicutaneous immunotherapy (EPIT) is the newest route of desensitization being
tested. This method is based on the avoidance of highly vascular areas which quickly
create a systemic immune response. Instead, a patch is placed to “[target] professional
allergen presenting cells (Langerhans cells of the epidermis) necessary for optimal
allergen presentation” (Anagnostou & Clark, 2014, p. 3). The first study involving
epicutaneous immunotherapy was done in a group of children with allergies to cow’s
milk. The study appeared to be well-tolerated and no systemic reactions occurred. A
similar trial of 4-25 year-olds with peanut allergies is currently in progress. This study
began in September 2013 and is expected to reach completion in March 2016 (NIAID,
2015) (Anagnostou & Clark, 2014).
Peanut Vaccine Therapy
In 2013, a study was conducted to research the effects of a newly-developed
peanut vaccine in allergic adults. The vaccine consisted of several modified peanut
proteins that were then encapsulated in heat/phenol killed E. coli. This vaccine was given
in a rectal administration called EMP-123 to a group of 10 allergic adults and five healthy
adults. Five of the allergic participants were unable to complete the study because the
reactions they sustained were too severe to continue. Of the other five, one had mild
symptoms and four had no reaction. The conclusion of the study was that significant
modifications, including possibly a change in administration route, need to be made
before any other trials can be performed using this peanut vaccine (Wood et al, 2013).
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Anti-IgE Therapy
Another method under trial is the use of an adjuvant to improve immunotherapy
results. Leung et al. conducted a randomized, double-blind, dose-ranging trial in 84
allergic participants. Some received a placebo, while the others were given an anti-IgE
molecule called TNX-901. The treatment phase lasted just four weeks, with doses being
given once a week. The results showed an increase in peanut reactivity threshold when
450mg of anti-IgE was concurrently administered. One limitation the researchers found
was that anti-IgE treatment is expensive when used long-term. To purchase one 150mg
vial of Omalizumab at a local pharmacy costs over 900 dollars. Depending on factors
such as length of treatment course, dosage and frequency of administration, and insurance
coverage, this could be an unaffordable long-term option for many families (GoodRx,
n.d.). In addition, details such as the administration timeframe needed to produce longlasting desensitization still need to be explored (Anagnostou & Clark, 2014).
Another study using anti-IgE in the form of Omalizumab as an adjuvant to OIT
was done by Schneider et al. in 2013. All 13 subjects were able to tolerate 4g of peanut
protein at the end of the therapy. As a result, the researchers believe that “Omalizumab
may facilitate rapid oral desensitisation in peanut allergic patients with high peanut
specific IgE levels at baseline” (Anagnostou & Clark, 2014, p. 3).
Peanut Proteins & Probiotic Therapy
Another type of adjuvant therapy currently being studied is the use of probiotic
therapy as an adjuvant to peanut immunotherapy. The results of one such study were
revealed earlier this year. Sixty-two participants were given a daily dose of the probiotic
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Lactobacillus rhamnosus in addition to undergoing a fixed schedule of build-up
immunotherapy. In order for seven children to remain unresponsive to peanuts after two
weeks, nine children needed to be treated. Thus, over 80% of the children who
participated showed tolerance to peanut intake at the end of the study. It was concluded
that the use of probiotic and peanut OIT is associated with decreased skin prick test
reaction and IgE levels. However, a greater number of adverse reactions was reported,
particularly during the maintenance phase. Further studies are needed to determine the
long-term effectiveness of combined therapy (Tang et al., 2015).
Many other studies utilizing probiotics have been done, but the majority of these
studies are done on mice. One study found that, “Oral administration of recombinant
Bacillus subtilis spores expressing CTB-Arah2 protected against peanut induced
anaphylaxis” (Zhou et al., 2015, p. AB29). There are many different probiotics that need
to be tested. Further testing, particularly more on human subjects, still needs to be
conducted to evaluate the effectiveness of probiotics combined with immunotherapy.
Study Evaluation Methods
The success of each study is determined by several different factors. Factors such
as the type and severity of participants’ reactions must be considered. Before the
immunotherapy treatment is initiated, baseline levels of immunoglobulin E, basophils,
and other relevant substances are typically measured. At certain times during the study,
these levels may be taken again to evaluate the current desensitization status. When the
study is complete, a final measurement will be taken to see what influence the therapy
had on the immune system and its response to the higher doses of peanut protein. One of
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the most important factors considered is how many milligrams of peanut protein the
individuals were able to tolerate. Most of the studies resulted in the participants being
able to tolerate at least 1000mg, even up to 10,000 mg in one case.
Positive Outcomes of Immunotherapy Treatment
Reduction in Allergic Reaction
In all of the studies aforementioned, at least some of the participants experienced
a successful reduction in their reaction to peanut consumption. This reduction was more
significant and more permanent in some than others. At the very least, the
immunotherapy treatment helps decrease allergic reactions with accidental consumption
of peanuts. Even if participants have to ingest a certain amount of peanuts per day, this is
more satisfactory than if they had not undergone immunotherapy. More studies need to
be done and correlating factors to success examined, but the positive results of
immunotherapy are substantial.
Adverse Effects and Limitations of Immunotherapy
Risks of Participation
While peanut immunotherapy and related experimental treatments for peanut
allergies have demonstrated substantial success and show significant potential, there are
still many drawbacks to implementation – from minor reactions to major events,
including fatalities.
Anaphylaxis or allergic reaction. The obvious major drawbacks currently faced
by peanut immunotherapy is the risk of allergic reaction involved in participation. Many
parents of those with peanut allergies understandably do not want place their child in
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danger for the sake of science. To avoid negative results as much as possible, many
precautions are taken during these studies. One such precaution has already been
examined – the ready supply of epinephrine and other emergency medical equipment in
case a participant becomes unable to tolerate a dosage. Another precaution involves the
early phase of selecting research participants. Typically those with a history of severe
anaphylaxis are excluded from participation in the study, since “[o]ther oral and GI side
effects, wheezing, worsening asthma, anaphylaxis have been shown to worsen or evolve
in some patients” (Moffat, 2014, para. 8).
Worsened symptoms of allergic reaction and other conditions. In addition to the
risk of anaphylaxis occurrence, there is a chance that subsequent reactions after
completion of the study may involve worsened symptoms, placing the individual at
greater risk. Also, the treatment may exacerbate previous comorbidities such as asthma.
Asthma tends to be common in children with peanut allergies; thus, many
immunotherapy participants must have their asthma monitored and taken into account in
the study findings. Because asthma increases the risk of adverse respiratory effects with
peanut exposure, many studies eliminate any potential participants who have severe
asthma. As Thyagarajan et al. (2010) notes, “The selection criterion for these protocols
excludes individuals with a history of anaphylaxis with hypotension, which may
represent many patients seeking this treatment in the clinical setting” (p. 32). In the study
performed by Blumchen et al. (2010), the four participants who were unable to continue
the study due to adverse effects all had been identified as having mild to moderate asthma
before beginning the study.
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A 2014 study evaluated the factors associated with increased adverse reactions in
104 children receiving peanut OIT. It was shown that children who have a history of
asthma, allergic rhinitis, and larger skin prick tests are at a higher risk of experiencing
adverse reactions. This information could be useful in screening high-risk participants for
future studies (Virkud, Vickery, Steele, Kulis, & Burks, (2015).
Eosinophilic esophagitis. Also at risk of worsening are gastrointestinal side
effects. In particular, a disorder known as eosinophilic esophagitis (EoE) has been a
recurring side effect noted in those who have been desensitized to peanuts through oral
immunotherapy. Eosinophilic esophagitis is “a disorder of the food tube characterized by
marked infiltration of a particular type of WBC (eosinophil) that can lead to pain,
narrowing and chronic inflammation” (Moffat, 2014, para. 8). An obvious correlation
between oral immunotherapy and EoE has been found, since EoE occurs in 10% of
patients who receive OIT, while only 0.0001% of the general population develops EoE
(Moffat, 2014).
Not a ‘Cure’
While studies have yielded encouraging results, peanut immunotherapy has not
yet reached the point of providing a complete cure for those with allergies. It is true that
many subjects have become desensitized to a certain amount of peanuts, but in some
cases, a reaction still occurs if the amount the person is exposed to exceeds the amount
the study desensitized them to or if they have gone a significant amount of time after the
study without ingesting peanuts. For many, in order for desensitization to be maintained,
they must continually consume a few peanuts or the equivalent amount of protein
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recommended every day. While desensitization is a positive and desired result of
immunotherapy whether a daily dose is continued or not, the ultimate goal of researchers
would be to induce tolerance of peanuts in these participants. Unfortunately, very few
individuals have actually demonstrated complete tolerance as a result of immunotherapy.
Varshney (2011) briefly describes the difference between antigen desensitization and
tolerance:
We use the term desensitization to signify a change in the amount of food antigen
needed to cause allergic symptoms; this state is dependent on regular antigen
exposure. In contrast, tolerance refers to long-term immunologic changes
associated with the ability to ingest a food without symptoms and without
ongoing therapy. (p. 8)
Moffat (2014) reiterates this point by noting that, “Outcomes studies seem to indicate that
peanut OIT does not lead to cure, and continuous exposure to peanuts is likely needed to
sustain desensitization” (para. 8). Additional studies have shown that although peanutallergic children are able to become desensitized by consumption of small amounts of
peanuts, this tolerance sometimes disappears. Thus, immunotherapy cannot yet be labeled
as a cure for peanut allergies (Rettner 2015).
Desensitization may not always continue, depending on the amount of peanut
protein the patient is exposed to and how long it has been since he ingested any.
However, some participants may mistakenly believe that they have been cured after
undergoing immunotherapy, causing an issue with false sense of security. These clients
may neglect to always have epi-pen with them or forget to keep taking the required
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maintenance dose because think will never have anaphylactic reaction again due to
desensitization. Appropriate education of the participants and family members is
necessary to correct this mindset (Thyagarajan, 2010).
Ethical Dilemmas Facing Physicians and Researchers
One of the main drawbacks to performing immunotherapy studies is the potential
of causing anaphylaxis in participants. Some researchers have pointed out that the risks
involved conflict with the medical provider’s Hippocratic obligation to “do no harm”
(Thyagarajan et al., 2010, p. 31). These same authors believe that because of the risks
associated with immunotherapy, those with peanut allergies should continue to practice
strict avoidance. Thyagarajan et al. (2010) states:
With current forms of OIT, as with other forms of immunotherapy, up to 18% of
patients undergoing treatment will not be able to endure the associated side
effects. In addition, accidental ingestions do pose a threat, with events occurring
in about 15% of children with peanut and tree nut allergy over a 4-year period.
The major issue to address is whether the likelihood of patients experiencing
accidental food reactions over a given period is more or less than the percentage
of patients who cannot tolerate OIT. (p. 31)
On the other hand, some argue that, “Many more deaths have resulted from
accidental exposure” than from immunotherapy and the psychological implications
associated with avoidance should not be ignored (Wasserman et al., 2011, p. 290). This
side believes that to do nothing for these clients would cause greater harm; “although OIT
is not without risk, it is a potentially life-altering treatment. Fully informed patients and
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parents should be free to choose the management approach that is best for themselves and
their families” (Wasserman et al., 2011, p. 290).
Future Research & Expectations
Before immunotherapy can be utilized as a reliable treatment for peanut allergies,
many more studies need to be performed in order to gain increased evidence of the
treatment’s effectiveness. Larger randomized studies will help provide a more accurate
picture of the benefits, drawbacks, and corresponding risk factors. The specific factors
that need to be examined include treatment methods, participant demographics, and other
details. Regarding treatment, further research is needed to determine the best route of
administration; the most effective preparation of peanut protein along with any adjuvant
medications; and appropriate dosage amounts and administration schedules. Selection of
study participants should include an assessment of related factors such as the age of the
children and severity of their allergy. Factors such as a high susceptibility to anaphylaxis;
sickness or menstruation during the therapy; incorrect timing of therapy administration;
excessive exertion following administration; and conditions such as asthma all have been
shown to cause an increased susceptibility to anaphylaxis. The majority of these
researchers agree that, while immunotherapy has potential, it is still “not ready for
clinical use” and significant advancements must be reached before it is a truly safe and
effective treatment modality (Thyagarajan et al., 2010, p. 31).
Anagnostou (2015) gives a brief overview of immunotherapy’s current progress
and areas needing further investigation:
Larger studies are needed to further improve safety and efficacy of this form of
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treatment. Patients will need to balance the frequent reactions occurring during
immunotherapy, with the risk of severe reactions due to accidental ingestion and
the possibility of successful desensitization, by the end of treatment. Long-term
tolerance following immunotherapy is still an area that requires further
investigation. Trials are also underway using immunotherapy by different routes
such as epicutaneous and sublingual. Other treatment options are also under
investigation such as the use of adjuvants (anti-IgE) in combination with OIT. (p.
71)
Another area currently under research that relates to the treatment of peanut
allergies is the correlation of genetics and genomics to allergy incidence. A study by
Hong et al. (2015) identified a loci specific to peanut allergy at 6p21.32, found in the
HLA-DR and -DQ gene region of 2197 study participants. It is believed that these gene
regions correlate to a high genetic risk of peanut allergy development (Hong et al., 2015).
This was “the first genome-wide association study (GWAS) that identified a genetic link
to well-defined peanut allergy” (para. 4). An interesting facet of these study results is that
although 20 percent of the study participants possess this susceptibility, not all of them
develop an allergy. Thus, “By identifying what environmental factors can alter DNA
methylation levels in people with genes that make them susceptible to peanut allergy,
researchers could potentially open a new avenue for prevention and treatment of peanut
allergy” (Johns Hopkins Bloomberg School of Public Health, 2015, para. 10).
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Conclusion
Of all the treatment types under research for peanut allergies, oral immunotherapy
appears to be the most successful method. Varshney (2011) states, “Further investigation
of this promising intervention will address outstanding issues and continue to refine
therapeutic protocols in hopes of offering an allergen-specific treatment option for food
allergy” (p. 8). The field of immunotherapy is quickly growing and changing in an
attempt to find a safe and successful means of treatment. As knowledge of peanut allergy
epidemiology increases and merges with expanding knowledge gained from clinical
trials, the ultimate goal of decreasing peanut allergy prevalence comes closer to
attainment.
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